13F Holdings
中文EN

NATR NATURES SUNSHINE PRODUCTS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 275053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.2%
TTM net income YoY-2.9%
TTM EPS YoY1.2%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR22.0%

Margins

Gross margin73.1%
Operating margin5.3%
Net margin3.1%
FCF margin2.2%
EBITDA margin8.1%

Returns

ROE8.8%
ROA5.5%
ROIC (approx.)21.5%
Asset turnover1.80x

Leverage & solvency

Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.56x
Interest coverage176.76x

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY2021*2021-12-31
Income statement
Revenue$480.14M$454.36M$445.32M$421.91M$444.08M
Cost of revenue$132.42M$129.68M$124.19M$122.15M$115.47M
Gross profit$347.72M$324.69M$321.13M$299.76M$328.62M
R&D expense$1.90M$1.70M$1.60M$1.50M$1.40M
SG&A expense$178.39M$164.00M$167.06M$153.12M$154.10M
Operating income$24.74M$20.09M$18.75M$16.26M$34.67M
Interest expense$98,000$146,000$69,000$249,000$250,000
Pretax income$29.81M$18.43M$20.20M$15.21M$31.82M
Income tax$9.36M$10.53M$3.79M$14.66M$1.61M
Net income$19.52M$7.70M$15.08M-$390,000$28.85M
EBITDA$38.59M$34.31M$30.57M$27.28M$45.83M
EPS (basic)1.080.410.79-0.021.45
EPS (diluted)1.060.400.77-0.021.42
Dividends declared per share———0.001.00
Weighted avg. shares (diluted)18.47M19.09M19.47M19.33M20.33M
Balance sheet
Cash & equivalents$93.89M$84.70M$82.37M$60.03M$86.18M
Receivables$8.60M$9.48M$8.83M$14.11M$8.87M
Inventory$68.31M$59.44M$66.89M$67.95M$60.85M
Current assets$178.84M$160.58M$165.82M$149.51M$164.67M
PP&E, net$32.91M$39.59M$45.00M$46.16M$50.86M
Total assets$261.15M$240.85M$249.77M$229.78M$258.87M
Current liabilities$78.54M$65.69M$76.75M$65.58M$76.67M
Short-term debt——$0$1.17M$1.24M
Long-term debt——$0$0$1.17M
Total debt——$0$1.17M$2.42M
Total liabilities$99.59M$79.86M$90.23M$82.73M$97.47M
Shareholders' equity$161.55M$155.31M$154.06M$142.91M$158.20M
Net debt——-$82.37M-$58.86M-$83.77M
Shares outstanding17.51M18.48M18.88M19.09M19.72M
Cash flow statement
Operating cash flow$35.32M$25.30M$41.23M$710,000$34.61M
Capital expenditure$6.48M$10.97M$10.48M$7.63M$6.67M
Free cash flow$28.84M$14.33M$30.75M-$6.92M$27.94M
Investing cash flow-$6.48M-$10.97M-$10.48M-$7.63M-$6.61M
Financing cash flow-$23.77M-$9.90M-$7.96M-$16.25M-$31.72M
Depreciation & amortization$13.84M$14.22M$11.82M$11.03M$11.16M
Stock-based compensation$5.78M$4.79M$4.89M$2.90M$3.73M
Dividends paid———$0$19.86M
Share buybacks$16.31M$8.86M$6.40M$13.57M$7.42M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.